In support of this, a recent study aiming to reduce the occurrence of ROP by administering human recombinant IGF-I showed that an increase in pro-inflammatory cytokines, e.g., interleukin-6, was associated with a subsequent decrease in IGF-I, and IGF-I administration reduced the occurrence of BPD [5,23]. The gene discussed is IL6; the disease is bronchopulmonary dysplasia.